HUP0105132A2 - Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions - Google Patents

Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions

Info

Publication number
HUP0105132A2
HUP0105132A2 HU0105132A HUP0105132A HUP0105132A2 HU P0105132 A2 HUP0105132 A2 HU P0105132A2 HU 0105132 A HU0105132 A HU 0105132A HU P0105132 A HUP0105132 A HU P0105132A HU P0105132 A2 HUP0105132 A2 HU P0105132A2
Authority
HU
Hungary
Prior art keywords
alkyl
aryl
general formula
preparing
pyrazinones
Prior art date
Application number
HU0105132A
Other languages
Hungarian (hu)
Inventor
Marx Degenhard
Ute Egerland
Norbert Höfgen
Stefan Szelenyi
Original Assignee
Arzneimittelwerk Dresden Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/en
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/en
Application filed by Arzneimittelwerk Dresden Gmbh. filed Critical Arzneimittelwerk Dresden Gmbh.
Publication of HUP0105132A2 publication Critical patent/HUP0105132A2/en
Publication of HUP0105132A3 publication Critical patent/HUP0105132A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A találmány (I) általános képletű imidazo[1,5-a]-pirido[3,2-e]-pirazinonok hatóanyagként való alkalmazására vonatkozik erekciósdiszfunkció (impotencia) kezelésére használható gyógyszerekelőállításában. A képletben A jelentése oxigénatom vagy =NH csoport,R1, R2 és R3 azonos vagy eltérő lehet, és jelentésük hidrogénatom vagyegyenes vagy elágazó láncú alkil-, alkenil- vagy alkinilcsoport, amelycsoportok adott esetben szubsztituálva lehetnek egy vagy több -OH, -SH, -NH2, -NH-alkil-, -N-dialkil-, -NH-aril-, -N-diaril-, -N-alkil,aril-, -NO2, -CN, -COOH, -COO-alkil-, -(C=O) -alkil-, -F, -C1, -Br, -I, -O-alkil-, -O-aril-, -S-alkil-, -S-aril-, -OSO2-alkil-, -OSO2-arilcsoporttal, mono-, bi- vagy triciklusos telített vagy egyszeresenvagy többszörösen telítetlen karbociklusos vagy 1-6 heteroatomottartalmazó heterociklusos csoporttal, amelyek adott esetbenszubsztituálva lehetnek. A találmány tárgyát képezi az (I) általánosképletű vegyületek előállítási eljárása, valamint az (I) általánosképletű vegyületek egy szűkebb körének alkalmazása hatóanyagkéntszívelégtelenség, pulmonáris hipertónia és vérellátás-csökkenésseljáró érbetegségek kezelésére használható gyógyászati készítményekelőállításában. ÓThe invention relates to the use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones of general formula (I) as active ingredients in the production of drugs for the treatment of erectile dysfunction (impotence). In the formula, A means an oxygen atom or =NH group, R1, R2 and R3 can be the same or different, and they mean a hydrogen atom or a straight or branched chain alkyl, alkenyl or alkynyl group, which groups can optionally be substituted by one or more -OH, -SH, - NH2, -NH-alkyl-, -N-dialkyl-, -NH-aryl-, -N-diaryl-, -N-alkyl,aryl-, -NO2, -CN, -COOH, -COO-alkyl-, - (C=O) -alkyl-, -F, -C1, -Br, -I, -O-alkyl-, -O-aryl-, -S-alkyl-, -S-aryl-, -OSO2-alkyl- , -OSO2-aryl group, mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocyclic or heterocyclic group containing 1-6 heteroatoms, which may be optionally substituted. The subject of the invention is the production process of the compounds of general formula (I), as well as the use of a narrower range of compounds of general formula (I) as active ingredients in the production of medicinal preparations for the treatment of heart failure, pulmonary hypertension and vascular diseases associated with reduced blood supply. HE

HU0105132A 1999-01-20 2000-01-14 Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions HUP0105132A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (en) 1999-01-20 1999-01-20 New and known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, useful as phosphodiesterase 5 inhibitors for treating erectile dysfunction
DE1999161302 DE19961302A1 (en) 1999-12-18 1999-12-18 Treatment of erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinones as phosphodiesterase inhibitors, some of which are also useful for treating cardiovascular disorders

Publications (2)

Publication Number Publication Date
HUP0105132A2 true HUP0105132A2 (en) 2002-05-29
HUP0105132A3 HUP0105132A3 (en) 2002-12-28

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105132A HUP0105132A3 (en) 1999-01-20 2000-01-14 Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions

Country Status (23)

Country Link
EP (1) EP1144410A2 (en)
JP (1) JP2002535330A (en)
KR (1) KR20010101603A (en)
CN (1) CN1344268A (en)
AR (1) AR022318A1 (en)
AU (1) AU2291200A (en)
BG (1) BG105714A (en)
BR (1) BR0007613A (en)
CA (1) CA2296224A1 (en)
CO (1) CO5190700A1 (en)
CZ (1) CZ20012627A3 (en)
EA (1) EA200100792A1 (en)
EE (1) EE200100377A (en)
HU (1) HUP0105132A3 (en)
ID (1) ID29790A (en)
IL (1) IL144156A0 (en)
IS (1) IS5987A (en)
LT (1) LT2001078A (en)
LV (1) LV12793B (en)
NO (1) NO20013334D0 (en)
SK (1) SK10322001A3 (en)
TR (1) TR200102121T2 (en)
WO (1) WO2000043392A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
JP2005513060A (en) * 2001-12-17 2005-05-12 アルタナ　ファルマ　アクチエンゲゼルシャフト New use of selective PDE5 inhibitors
FR2835741B1 (en) * 2002-02-12 2006-05-05 Oreal NOVEL 6-ALCOXY-2,3-DIAMINOPYRIDINE COUPLINGS USEFUL FOR DYING KERATIN FIBERS
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
DE10325813B4 (en) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxis and / or therapy in portal hypertension
CN101106997A (en) 2004-08-17 2008-01-16 约翰·霍普金斯大学 PDE5 inhibitor compositions and methods for treating cardiac indications
ES2536906T3 (en) * 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Quinoxaline derivative
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
JP2011505366A (en) 2007-11-30 2011-02-24 ワイス・エルエルシー Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10
MX370433B (en) 2011-10-10 2019-12-13 H Lundbeck As Pde9i with imidazo pyrazinone backbone.
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
JP5842640B2 (en) * 2012-01-31 2016-01-13 株式会社東洋新薬 Phosphodiesterase 3 inhibitor
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
DK3303339T3 (en) 2015-07-07 2021-04-12 H Lundbeck As PDE9 INHIBITORS WITH THE IMIDAZOTRIAZINON SKELELINE AND IMIDAZOPYRAZINON SKELELINE FOR THE TREATMENT OF PERIOD DISEASES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (en) * 1995-03-24 1996-09-26 Asta Medica Ag New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation

Also Published As

Publication number Publication date
SK10322001A3 (en) 2002-07-02
HUP0105132A3 (en) 2002-12-28
ID29790A (en) 2001-10-11
JP2002535330A (en) 2002-10-22
IS5987A (en) 2001-06-29
WO2000043392A3 (en) 2000-09-28
AU2291200A (en) 2000-08-07
TR200102121T2 (en) 2002-01-21
NO20013334L (en) 2001-07-05
CO5190700A1 (en) 2002-08-29
BG105714A (en) 2002-02-28
CZ20012627A3 (en) 2002-01-16
EP1144410A2 (en) 2001-10-17
IL144156A0 (en) 2002-05-23
EE200100377A (en) 2002-10-15
CA2296224A1 (en) 2000-07-20
CN1344268A (en) 2002-04-10
LV12793B (en) 2002-05-20
WO2000043392A2 (en) 2000-07-27
LT2001078A (en) 2002-08-26
LV12793A (en) 2002-02-20
AR022318A1 (en) 2002-09-04
KR20010101603A (en) 2001-11-14
EA200100792A1 (en) 2002-10-31
BR0007613A (en) 2001-10-30
NO20013334D0 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
HUP0105132A2 (en) Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions
GT200000168A (en) PHARMACEUTICALLY ACTIVE COMPOUNDS.
HUP0300846A2 (en) Imidazopyrimidinederivatives and triazolopyrimidine derivatives, process for their preparation and pharmaceutical compositions containing the compounds
HUP0000720A2 (en) Imidazo [1,2-a] pyridine derivatives, process for their preparation, pharmaceutical formulation containing them and their use
JP2004500425A (en) Use of cyclic GMP-specific phosphodiesterase inhibitors for the treatment of Parkinson's disease
HUP0202795A2 (en) Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use
HUP0401984A2 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
DE69830503D1 (en) TABLET WITH EXTENDED ACTIVE SUBSTANCE FOR THE TREATMENT OF PARKINSONTAL DISEASE
EP0702555A1 (en) Pyrazolopyrimidinones for the treatment of impotence
HK1135964A1 (en) Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics
MX2010004819A (en) [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta.
ES2166270A1 (en) 8-PHENYL-6,9-DIHYDRO- 1,2,4]TRIAZOLO 3,4- i i /i ]PURIN-5-ONE DERIVATIVES
ES2191754T3 (en) PHENYL-DIHYDROBENZOFURANS.
NO20065078L (en) Inhalation powder formulations containing enantiomerically pure beta agonists.
ATE402707T1 (en) IMIDAZOÄ1,5AUTRIAZOLÖ1,5DUBENZODIAZEPINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS
HUP0300551A2 (en) Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction and pharmaceutical compositions containing them
MY133995A (en) 6-phenylpyrrolopyrimidinedione derivatives
PT102457A (en) PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE INHIBITOR OF PDE5
HUP0100558A2 (en) S-oxide and s,s,-dioxide tetrahydrothiopyran phenyloxazolidinones, their use for preparation of pharmaceutical compositions and process for determining the inhibitory activity of compounds to human monoamino oxidase
HUP0001922A2 (en) Pyrazolo[4,3-c]-pyridine derivatives, pharmaceutical compositions thereof against insulin resistance, intermediates and process for their preparation
DE59610031D1 (en) CYCLOHEXYLDIHYDROBENZOFURANE
HUP0303480A2 (en) 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine derivatives, as crf-antagonists and pharmaceutical compositions containing them
SE9701304D0 (en) Compounds
HUP9900438A2 (en) Use of pyrazolo[4,3-d]pyrimidin-7-one derivatives for the preparation of pharmaceutical compositions treaing impotence due to spinal cord injury
ATE397606T1 (en) PYRAZINO(1',2':1,6)-PYRIDO(3,4-B) INDOLE-1,4-DIONE DERIVATIVES